PeriphaGen's lead product, PGN-503, is designed to prevent or treat peripheral neuropathy in patients receiving chemotherapy, but that's just the start of what we can do.


PeriphaGen’s NET vector technology allows for targeted delivery to specific sensory nerves via a simple intradermal skin injection, thus our lead products have focused on treating peripheral nerve disorders such as neuropathy and chronic pain. However, the unique capabilities of our vector platform can be exploited to address a variety therapeutic areas and uses.


NET Platform for Neuropathy - PGN-503

NET Platform for Pain

Joint-Deleted Vectors for Large Payloads and Genetic Engineering

Oncolytic Viruses

HSV-1 Manufacturing Services

Copyright (C) 2016 | PeriphaGen, Inc; All rights reserved

  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon